Friday, 15 January 2016

08.30 - 08.40  Welcome
M. Brausi, Modena (IT)
P. Chlosta, Cracow (PL)

08.40 - 09.00  Opening address
Polish Urological Association (PUA) enjoys a strong partnership with the EAU
P. Chlosta, Cracow (PL)

09.00 - 13.15  Prostate cancer I: Diagnosis and active surveillance
Chairs: M. Brausi, Modena (IT)
B. Djavan, Vienna (AT)

09.00 - 09.20  Can MRI identify prostate cancer in men with PSA less than 3 ng/ml?
J. Hugosson, Gothenburg (SE)

09.20 - 09.35  How reliable is a negative MRI?
J. Futterer, Nijmegen (NL)

09.35 - 09.50  How and in which patients to perform a TRUS-MRI fusion biopsy? (Video)
T. Kuru, Cologne (DE)

09.50 - 10.05  Discussion

10.05 - 10.20  Active surveillance: Do we know the long term risk?
R. Godtman, Gothenburg (SE)

10.20 - 10.30  Are there any new reliable triggers in active surveillance?
P. Carroll, San Francisco (US)

10.30 - 10.45  The use of MRI in the follow-up of patients on AS: Results of a prospective study
M. Colombel, Lyon (FR)

10.45 - 11.00  Case presentation and discussion
J. Barentsz, Nijmegen (NL)

11.00 - 11.15  Refreshment break
11.15 – 12.15 DEBATE: Treatment of intermediate risk patients
   Chairs: P. Carroll, San Francisco (US)
          J. Hugosson, Gothenburg (SE)

11.15 – 11.30 What is the intermediate risk in 2015?
   S. Joniau, Leuven (BE)

11.30 – 11.35 Discussion

11.35 – 11.50 Focal therapy: A critical review
   W. Artibani, Verona (IT)

11.50 – 12.05 Extended lymphadenectomy: A critical review
   P. Carroll, San Francisco (US)

12.05 – 12.15 Discussion

12.15 – 12.30 ESUR Lecture: Which biomarkers are ready to use in clinical practice?
   Z. Culig, Innsbruck (AT)

12.30 – 12.35 Discussion

12.35 – 12.50 Robotic surgery for cT3 prostate cancer (Video)
   B. Rocco, Milan (IT)

12.50 – 13.05 Evolving role of open radical prostatectomy in high risk prostate cancer in the robotic era (Video)
   B. Djavan, Vienna (AT)

13.05 – 13.15 Discussion

13.15 – 14.00 Lunch

14.00 – 16.10 Renal cancer: Localised and locally advanced
   Chairs: M. Laguna, Amsterdam (NL)
          H. Ozen, Ankara (TR)

14.00 – 14.15 Utility of nephrometric scores in kidney cancer surgery
   S. Brookman-May, Munich (DE)

14.15 – 14.25 Discussion

14.25 – 14.40 Perfusion/reperfusion injury following ischemia for nephron sparing surgery
   G. Janetschek, Salzburg (AT)

14.40 – 15.15 DEBATE: Laparoscopic partial nephrectomy: Rest in peace?

14.40 – 14.50 Point of view of robotic surgeon (Video)
   A. Mottrie, Aalst (BE)

14.50 – 15.00 Point of view of laparoscopic surgeon (Video)
   J. Rassweiler, Heilbronn (DE)

15.00 – 15.10 Point of view of open surgeon (Video)
15.10 – 15.15  Discussion

15.15 – 15.30  Tumour enucleation vs partial nephrectomy: Long term results (Video)
A. Minervini, Florence (IT)

15.30 – 15.40  Discussion

15.40 – 16.00  Avoiding complications and troubleshooting during robotic partial nephrectomy (Video)
V. Pansadoro, Rome (IT)

16.00 – 16.10  Discussion

16.10 – 16.30  Refreshment break

16.30 – 18.00  Urothelial and bladder cancer
Chairs: B. Bochner, New York (US)
G. Thalmann, Berne (CH)

16.30 – 16.40  Bladder Cancer Prevention Programme: A global initiative
M. Brausi, Modena (IT)

16.40 – 16.50  Discussion

16.50 – 17.00  Gender inequalities in bladder cancer presentation and outcome
J. Dobruch, Warsaw (PL)

17.00 – 17.15  Regenerative medicine following radical cystectomy
M. Pokrywczyńska, Bydgoszcz (PL)

17.15 – 17.25  Discussion

17.25 – 17.40  Should robotic radical cystectomy become a new standard: Results of a prospective, randomised study
B. Bochner, New York (US)

17.40 – 18.00  Discussion
Saturday, 16 January 2016

08.30 – 10.25  Prostate cancer II: Diagnosis and management of local relapse
  Chairs: F. Montorsi, Milan (IT)
          M. Wirth, Dresden (DE)

08.30 – 08.45  Imaging modalities to localise the anatomic sites of recurrences
  U. Haberkorn, Heidelberg (DE)

08.45 – 08.55  Discussion

08.55 – 09.10  Recent data on salvage lymphadenectomy
  C. Jilg, Freiburg (DE)

09.10 – 09.25  Discussion

09.25 – 09.40  Current developments in salvage radiation therapy (SRT)
  B. Jereczek, Milan (IT)

09.40 – 10.25  Salvage treatments of local recurrences after radiation therapy

  09.40 – 09.50  Radical prostatectomy
                 M. Wirth, Dresden (DE)

  09.50 – 10.00  Brachytherapy
                 A. Bossi, Villejuif (FR)

  10.00 – 10.10  HIFU
                 M. Colombel, Lyon (FR)

10.10 – 10.25  Discussion

10.25 – 11.20  Testis and penile cancer
  Chairs: A. Govorov, Moscow (RU)
          O. Hakenberg, Rostock (DE)

  10.25 – 10.40  Update of testis cancer guidelines
                 Z. Jablonowski, Lodz (PL)

  10.40 – 10.55  Primary penile sparing treatment approaches
                 C. Protzel, Rostock (DE)

  10.55 – 11.10  Neo-adjuvant vs adjuvant systemic chemotherapy for penile cancer patients with bulky
                 inguinal adenopathy
                 A. Necchi, Milan (IT)

11.10 – 11.20  Discussion

11.20 – 11.40  Refreshment break
11.40 – 13.50  Urothelial cancer II: Non-muscle invasive, muscle invasive and UUT
Chairs: M. Colombel, Lyon (FR)
        J. Palou, Barcelona (ES)

11.40 – 11.55  Alternative adjuvant treatments for NMIBC in the BCG shortage era
J. Palou, Barcelona (ES)

11.55 – 12.05  Discussion

12.05 – 12.40  Challenging the EAU Guidelines
Neo-adjuvant chemotherapy for MIBC should be administered: Pro/Con

12.05 – 12.20  Pro
G. Gakis, Tubingen (DE)

12.20 – 12.35  Con
G. Thalmann, Berne (CH)

12.35 – 12.40  Discussion

12.40 – 12.55  Salvage cystectomy after radiotherapy: Type of diversion and morbidity
J. Catto, Sheffield (GB)

12.55 – 13.10  Discussion

13.10 – 13.50  MDT in uro-oncology
Difficult cases in high risk urothelial cancer
Chairs: B. Malavaud, Toulouse (FR)
        L. Turkeri, Istanbul (TR)
        Panel: E. Comperat, Paris (FR)
          P. Gontero, Turin (IT)
          L. Nyk, Warsaw (PL)
          S. Osanto, Leiden (NL)
With the aim to boost links with promising young clinicians specialising in urological cancers, the EAU Section of Oncological Urology (ESOU) has developed the STEPS programme (Sessions To Evaluate Progress in the management of urological cancers). Piloted in 2011, STEPS will celebrate its 6th Anniversary in January 2016 at the 13th ESOU Meeting in Warsaw.

Twenty young clinicians who are already practising, or who have a firm career interest, in onco-urology are selected annually through an open application process to meet established experts in the fields of prostate, bladder, renal and testicular cancer. To date 60 young clinicians have already enjoyed this unique learning and networking experience, with feedback being overwhelmingly positive.

STEPS allows young clinicians take part in a closed-door case discussion which aims to:

- Offer an innovative educational opportunity to selected young clinicians
- Strengthen ties between ESOU and talented younger clinicians in uro-oncology
- Boost the participant’s professional network with both established and emerging experts in uro-oncology.
### Sunday, 17 January 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 10.00</td>
<td>Prostate cancer III: Localised and metastatic</td>
<td>A. Briganti, Milan (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. Calais da Silva, Lisbon (PT)</td>
</tr>
<tr>
<td>09.00 – 09.15</td>
<td>Neo-adjuvant therapy before radical prostatectomy: A re-opened chapter? Current and future role</td>
<td>M. Spahn, Berne (CH)</td>
</tr>
<tr>
<td>09.15 – 09.20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09.20 – 09.35</td>
<td>Intermittent hormone therapy: Not a standard for many urologists and oncologists. Why?</td>
<td>F. Calais da Silva, Lisbon (PT)</td>
</tr>
<tr>
<td>09.35 – 09.40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09.40 – 09.55</td>
<td>Radical prostatectomy in oligo-metastatic disease</td>
<td>A. Heidenreich, Cologne (DE)</td>
</tr>
<tr>
<td>09.55 – 10.00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10.00 – 11.15</td>
<td>The best of uro-oncology in 2015</td>
<td>P. Radziszewski, Warsaw (PL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Rocco, Milan (IT)</td>
</tr>
<tr>
<td>10.00 – 10.15</td>
<td>Kidney cancer</td>
<td>H. Langenhuijsen, Nijmegen (NL)</td>
</tr>
<tr>
<td>10.15 – 10.30</td>
<td>Bladder cancer</td>
<td>A. Noon, Sheffield (GB)</td>
</tr>
<tr>
<td>10.30 – 10.45</td>
<td>Testis cancer</td>
<td>D. Pfister, Aachen (DE)</td>
</tr>
<tr>
<td>10.45 – 11.00</td>
<td>Prostate cancer</td>
<td>P. Ost, Ghent (BE)</td>
</tr>
<tr>
<td>11.00 – 11.15</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>Refreshment break</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>11.45 - 13.00</td>
<td><strong>Prostate cancer IV</strong></td>
<td>W. Artibani, Verona (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Heidenreich, Cologne (DE)</td>
</tr>
<tr>
<td>11.45 - 12.00</td>
<td>Early androgen receptor inhibitor therapy in locally advanced prostate cancer: Latest results</td>
<td>A. Heidenreich, Cologne (DE)</td>
</tr>
<tr>
<td>12.00 - 12.05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.05 - 12.20</td>
<td>Sequencing of medical therapy in CRPC</td>
<td>O. Caffo, Trento (IT)</td>
</tr>
<tr>
<td>12.20 - 12.25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>12.25 - 12.40</td>
<td>Radium 223 dichloride for metastatic CRPC: The urologist's perspective</td>
<td>P. Chlosta, Cracow (PL)</td>
</tr>
<tr>
<td>12.40 - 13.00</td>
<td>Announcement of ESOU Achievement Award and meeting close</td>
<td>M. Brausi, Modena (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Chlosta, Cracow (PL)</td>
</tr>
</tbody>
</table>